Omar K Siddiqi1, Melissa A Elafros1, Christopher M Bositis1, Igor J Koralnik1, William H Theodore1, Jason F Okulicz1, Lisa Kalungwana1, Michael J Potchen1, Izukanji Sikazwe1, Gretchen L Birbeck2. 1. From the Global Neurology Program, Department of Neurology (O.K.S., I.J.K.), and Center for Virology and Vaccines Research, Department of Internal Medicine (O.K.S., I.J.K.), Beth Israel Deaconess Medical Center, Boston, MA; Department of Internal Medicine (O.K.S.), University of Zambia School of Medicine (UNZA-SOM), Lusaka; College of Human Medicine (M.A.E.), Michigan State University (MSU), East Lansing; Greater Lawrence Family Health Center (C.M.B.); Clinical Epilepsy Division (W.H.T.), United States National Institutes of Health, Bethesda, MD; HIV Evaluation Unit (J.F.O.), Infectious Disease Service, San Antonio Military Medical Center, TX; Department of Psychiatry (L.K.), University of Zambia (UNZA), Lusaka; Neuroradiology Division, Department of Imaging Sciences (M.J.P.), and Strong Epilepsy Center, Department of Neurology (G.L.B.), University of Rochester, NY; Department of Radiology (M.J.P.), Lusaka Apex Medical University; Centre for Infectious Disease Research in Zambia (CIDRZ) (I.S.), Lusaka; and Epilepsy Care Team (G.L.B.), Chikankata Hospital, Mazabuka, Zambia. 2. From the Global Neurology Program, Department of Neurology (O.K.S., I.J.K.), and Center for Virology and Vaccines Research, Department of Internal Medicine (O.K.S., I.J.K.), Beth Israel Deaconess Medical Center, Boston, MA; Department of Internal Medicine (O.K.S.), University of Zambia School of Medicine (UNZA-SOM), Lusaka; College of Human Medicine (M.A.E.), Michigan State University (MSU), East Lansing; Greater Lawrence Family Health Center (C.M.B.); Clinical Epilepsy Division (W.H.T.), United States National Institutes of Health, Bethesda, MD; HIV Evaluation Unit (J.F.O.), Infectious Disease Service, San Antonio Military Medical Center, TX; Department of Psychiatry (L.K.), University of Zambia (UNZA), Lusaka; Neuroradiology Division, Department of Imaging Sciences (M.J.P.), and Strong Epilepsy Center, Department of Neurology (G.L.B.), University of Rochester, NY; Department of Radiology (M.J.P.), Lusaka Apex Medical University; Centre for Infectious Disease Research in Zambia (CIDRZ) (I.S.), Lusaka; and Epilepsy Care Team (G.L.B.), Chikankata Hospital, Mazabuka, Zambia. gretchen_birbeck@urmc.rochester.edu.
Abstract
OBJECTIVE: To identify the etiology of new-onset seizure in HIV-infected Zambian adults and identify risk factors for seizure recurrence. METHODS: A prospective cohort study enrolling HIV-infected adults with new-onset seizure within 2 weeks of index seizure obtained clinical, laboratory, and neuroimaging data to determine seizure etiology. Participants were followed to identify risk factors for seizure recurrence. Risk factors for mortality were examined as mortality rates were unexpectedly high. RESULTS: Eighty-one patients with CSF for analysis were enrolled and followed for a median of 306 days (interquartile range 61-636). Most (91%) were at WHO stage III/IV and 66 (81%) had a pre-seizure Karnofsky score ≥50. Prolonged or multiple seizures occurred in 46 (57%), including 12 (15%) with status epilepticus. Seizure etiologies included CNS opportunistic infections (OI) in 21 (26%), hyponatremia in 23 (28%), and other infections in 8 (10%). OIs included Cryptococcus (17%), JC virus (7%) and 5% each for tuberculosis, cytomegalovirus, and varicella-zoster virus. No etiology could be identified in 16 (20%). Thirty (37%) patients died during follow-up and 20 (25%) had recurrent seizures with survival being the only identifiable risk factor. CONCLUSIONS: HIV-infected adults with new-onset seizure in Zambia often have advanced HIV disease with OI being the most frequent seizure etiology. Seizure recurrence is common but no risk factors for recurrence other than survival were identified. These findings suggest an urgent need for immune reconstitution in this population. Initiating treatment for seizure prophylaxis where only enzyme-inducing antiepileptic medications are available could threaten antiretroviral efficacy.
OBJECTIVE: To identify the etiology of new-onset seizure in HIV-infected Zambian adults and identify risk factors for seizure recurrence. METHODS: A prospective cohort study enrolling HIV-infected adults with new-onset seizure within 2 weeks of index seizure obtained clinical, laboratory, and neuroimaging data to determine seizure etiology. Participants were followed to identify risk factors for seizure recurrence. Risk factors for mortality were examined as mortality rates were unexpectedly high. RESULTS: Eighty-one patients with CSF for analysis were enrolled and followed for a median of 306 days (interquartile range 61-636). Most (91%) were at WHO stage III/IV and 66 (81%) had a pre-seizure Karnofsky score ≥50. Prolonged or multiple seizures occurred in 46 (57%), including 12 (15%) with status epilepticus. Seizure etiologies included CNS opportunistic infections (OI) in 21 (26%), hyponatremia in 23 (28%), and other infections in 8 (10%). OIs included Cryptococcus (17%), JC virus (7%) and 5% each for tuberculosis, cytomegalovirus, and varicella-zoster virus. No etiology could be identified in 16 (20%). Thirty (37%) patients died during follow-up and 20 (25%) had recurrent seizures with survival being the only identifiable risk factor. CONCLUSIONS:HIV-infected adults with new-onset seizure in Zambia often have advanced HIV disease with OI being the most frequent seizure etiology. Seizure recurrence is common but no risk factors for recurrence other than survival were identified. These findings suggest an urgent need for immune reconstitution in this population. Initiating treatment for seizure prophylaxis where only enzyme-inducing antiepileptic medications are available could threaten antiretroviral efficacy.
Authors: Michael J Potchen; Sam D Kampondeni; Khalid Ibrahim; Joseph Bonner; Karl B Seydel; Terrie E Taylor; Gretchen L Birbeck Journal: Neurology Date: 2013-08-06 Impact factor: 9.910
Authors: Lisa Kalungwana; Melissa A Elafros; Omar K Siddiqi; Christopher M Bositis; Izukanji Sikazwe; Igor J Koralnik; William H Theodore; Gretchen L Birbeck Journal: Am J Trop Med Hyg Date: 2014-10-13 Impact factor: 2.345
Authors: Radha Rajasingham; Joshua Rhein; Kate Klammer; Abdu Musubire; Henry Nabeta; Andrew Akampurira; Eric C Mossel; Darlisha A Williams; Dave J Boxrud; Mary B Crabtree; Barry R Miller; Melissa A Rolfes; Supatida Tengsupakul; Alfred O Andama; David B Meya; David R Boulware Journal: Am J Trop Med Hyg Date: 2014-11-10 Impact factor: 2.345
Authors: Gretchen L Birbeck; Jacqueline A French; Emilio Perucca; David M Simpson; Henry Fraimow; Jomy M George; Jason F Okulicz; David B Clifford; Houda Hachad; René H Levy Journal: Epilepsia Date: 2012-01 Impact factor: 5.864
Authors: I Sikazwe; M A Elafros; C M Bositis; O K Siddiqi; I J Koralnik; L Kalungwana; W H Theodore; J F Okulicz; M J Potchen; G L Birbeck Journal: HIV Med Date: 2015-07-22 Impact factor: 3.180
Authors: Matthew J Kelly; Laura A Benjamin; Katharine Cartwright; Katherine M B Ajdukiewicz; Danielle B Cohen; Mavis Menyere; Sareen Galbraith; Malcolm Guiver; Florian Neuhann; Tom Solomon; David G Lalloo; Robert S Heyderman Journal: J Infect Dis Date: 2011-11-09 Impact factor: 5.226
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Mary C Spiciarich; Jane R von Gaudecker; Laura Jurasek; Dave F Clarke; Jorge Burneo; Jorge Vidaurre Journal: Curr Neurol Neurosci Rep Date: 2019-05-01 Impact factor: 5.081
Authors: Allison Navis; Ifunanya Dallah; Charles Mabeta; Kalo Musukuma; Omar K Siddiqi; Christopher M Bositis; Igor J Koralnik; Harris A Gelbard; William H Theodore; Jason F Okulicz; Brent A Johnson; Izukanji Sikazwe; David R Bearden; Gretchen L Birbeck Journal: Epilepsia Date: 2020-10-21 Impact factor: 5.864
Authors: Mathura Ravishankar; Ifunanya Dallah; Manoj Mathews; Christopher M Bositis; Musaku Mwenechanya; Lisa Kalungwana-Mambwe; David Bearden; Allison Navis; Melissa A Elafros; Harris Gelbard; William H Theodore; Igor J Koralnik; Jason F Okulicz; Brent A Johnson; Clara Belessiotis; Ornella Ciccone; Natalie Thornton; Melissa Tsuboyama; Omar K Siddiqi; Michael J Potchen; Izukanji Sikazwe; Gretchen L Birbeck Journal: Epilepsia Open Date: 2022-04-01
Authors: Melissa A Elafros; Brent A Johnson; Omar K Siddiqi; Jason F Okulicz; Izukanji Sikazwe; Christopher M Bositis; Michael J Potchen; Igor J Koralnik; William H Theodore; Lisa Kalungwana; Gretchen L Birbeck Journal: BMC Neurol Date: 2018-12-07 Impact factor: 2.474
Authors: William P Howlett; Sarah J Urasa; Venance P Maro; Richard W Walker; Kajiru G Kilonzo; Patrick J Howlett; Marieke Cj Dekker Journal: Afr Health Sci Date: 2022-03 Impact factor: 1.108